Compare
Cerenome, Inc. vs Picard Medical, Inc. vs Lucid Diagnostics Inc. vs Intelligent Bio Solutions Inc.
| Latest fiscal year | Cerenome, Inc. CNSY | Picard Medical, Inc. PMI | Lucid Diagnostics Inc. LUCD | Intelligent Bio Solutions Inc. INBS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $5.21M | $4.94M | $4.71M | $4.22M |
| Revenue growth (YoY) | -10.5% | +12.5% | +8.3% | +38.1% |
| Gross margin | n/a | -4.1% | -41.7% (computed) | 48.6% |
| Operating margin | -293.5% | -268.4% | n/m | -299.1% |
| Net margin | -429.4% | -546.6% | n/m | -294.9% |
| Net income | -$22.39M | -$27.00M | -$58.01M | -$12.43M |
| EPS (Diluted) | -$0.29 | n/a | n/a | -$8.44 |
| Operating cash flow | -$20.77M | -$15.67M | -$46.48M | -$11.93M |
| Free cash flow | -$20.84M | n/a | -$46.68M | -$12.05M |
| Cash & equivalents | $4.26M | $7.45M | n/a | $3.99M |
| Total assets | $16.32M | $22.55M | $40.45M | $11.94M |
| Total liabilities | $12.33M | $18.76M | $29.51M | $6.65M |
| Shareholders' equity | $4.00M | $3.79M | $10.94M | $5.51M |
| Return on year-end equity | -560.2% | -712.6% | -530.4% | -225.6% |
| Shares outstanding | 138.68M | 73.70M | 131.10M | 2.91M |
Revenue, most recent five fiscal years
| Fiscal year | Cerenome, Inc. | Picard Medical, Inc. | Lucid Diagnostics Inc. | Intelligent Bio Solutions Inc. |
|---|---|---|---|---|
| Latest | $5.21M Ended 2025-12-31 | $4.94M Ended 2025-12-31 | $4.71M Ended 2025-12-31 | $4.22M Ended 2026-06-30 |
| 1 year earlier | $5.82M Ended 2024-12-31 | $4.39M Ended 2024-12-31 | $4.35M Ended 2024-12-31 | $3.05M Ended 2025-06-30 |
| 2 years earlier | $4.91M Ended 2023-12-31 | n/a | $2.43M Ended 2023-12-31 | $3.11M Ended 2024-06-30 |
| 3 years earlier | n/a | n/a | $377.0K Ended 2022-12-31 | $1.26M Ended 2023-06-30 |
| 4 years earlier | n/a | n/a | $500.0K Ended 2021-12-31 | $437.1K Ended 2022-06-30 |